🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Refractory B Acute Lymphoblastic Leukemia

    phase 1 small molecule terminated

    1 trial

  2. Dual-Wavelength Quantitative Fluorescence Endoscopy for Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer: A Phase I Multicenter Feasibility and Safety Study

    Disc Medicine

    Esophageal cancer

    phase 1 other active

    1 trial

  3. Dupilumab

    Regeneron UK Limited

    Atopic Disorders

    phase 1 small molecule completed

    1 trial

  4. Dupilumab (SAR231893)

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  5. Dupilumab (SAR231893)

    Regeneron UK Limited

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  6. EBV immunological agent

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Tumor

    phase 1 mab active

    1 trial

  7. EDG-15400

    Edgewise Therapeutics

    Healthy Adults

    phase 1 small molecule active

    1 trial

  8. EDG-5506

    Edgewise Therapeutics

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  9. EDG-5506

    Edgewise Therapeutics

    Muscular Dystrophies

    phase 1 small molecule completed

    1 trial

  10. EDG-5506 Tablet

    Edgewise Therapeutics

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  11. EDG-7500

    Edgewise Therapeutics

    Healthy Adult Participants

    phase 1 small molecule active

    1 trial

  12. EDG-7500

    Edgewise Therapeutics

    Renal Impairments

    phase 1 small molecule completed

    1 trial

  13. EDG-7500

    Edgewise Therapeutics

    Hepatic Impairment (HI)

    phase 1 small molecule active

    1 trial

  14. EDG-7500

    Edgewise Therapeutics

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  15. ELVN-001

    Enliven Therapeutics

    CML (Chronic Myelogenous Leukemia)

    phase 1 small molecule active

    1 trial

  16. ELX-02

    Eloxx Pharmaceuticals

    Genetic Diseases

    phase 1 small molecule terminated

    1 trial

  17. Effect of SAR445611 on inflammatory responses following LPS challenge study in healthy participants

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 1 other active

    1 trial

  18. Efficacy of LCAR-T2C CAR-T cells

    Nanjing Legend Biotech Co.

    T Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  19. Efficacy of LCAR-T2C CAR-T cells

    Nanjing Legend Biotech Co.

    CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

    phase 1 small molecule terminated

    1 trial

  20. Elagolix

    NEUROCRINE BIOSCIENCES INC

    Folliculogenesis

    phase 1 small molecule completed

    1 trial

  21. Ethinyl Estradioll/Levonorgestrel (EE/LNG)

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  22. Evaluation of AG-181 in Subjects 18 to 69 Years of Age With Phenylketonuria

    Lacuna Pharma Pty Ltd

    Phenylketonuria

    phase 1 other active

    1 trial

  23. Evaluation of the bioavailability of two transdermal gel preparations containing 0.1% w/w estradiol under fasting conditions: Estradiol/INTERMED gel 0.1% w/w (Test) vs. ESTREVA® 0.1%, gel (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy postmenopausal women

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  24. Evinacumab

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources